IDE, insulin degrading enzyme, 3416

N. diseases: 71; N. variants: 19
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease
0.600 AlteredExpression disease BEFREE Moreover, we found that the levels of miR-7 are also elevated in brains of AD patients; this inversely correlates with the expression of its target genes IRS-2 and IDE. 31501273 2019
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease
0.600 Biomarker disease BEFREE Among these, insulin-degrading enzyme (IDE) degrades amyloid-β peptide (Aβ), the core pathological product of Alzheimer's disease (AD), whereas β-amyloid cleavage enzyme 1 (BACE1) hydrolyzes amyloid-β protein precursor (AβPP). 31403945 2019
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease
0.600 Biomarker disease BEFREE The findings suggest that IDE and RCAN1 differentially modulate brain insulin signaling in relation to AD severity and ApoE genotype. 31193223 2019
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease
0.600 Biomarker disease BEFREE Membrane metalloendopeptidase (MME) and insulin-degrading enzyme (IDE) are two types of proteases that could cleave beta-amyloid (Aβ) peptides generated by neuron cells of AD patients. 31151136 2019
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease
0.600 AlteredExpression disease BEFREE These plant metabolites have been shown to ameliorate AD by increasing the expression of insulin degrading enzyme (IDE), neprilysin (NEP), PPAR-γ, and α-secretase, and decreasing the expression of β-secretase (BACE-1) to reduce the levels of Aβ oligomers (Aβ<sub>O</sub>) deposition in brain neurons. 30877973 2019
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease
0.600 Biomarker disease BEFREE Therefore, changes in brain cholesterol levels by modifying the mGSH content would play a key role in IDE and NEP-mediated proteolytic elimination of Aβ peptides and AD progression. 31376793 2019
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease
0.600 Biomarker disease BEFREE As for Alzheimer's disease (AD) related pathology, chia seed not only increased α-secretase such as ADAM10 and insulin degrading enzyme (IDE), but also increased β-secretase including beta-secretase 1 (BACE1) and cathepsin B, with an overall effects of elevation in the hippocampal Aβ<sub>42</sub> level; chia seed slightly reduced p-Tauser404 in the hippocampus; while an elevation in neuro-inflammation with the activation of glial fibrillary acidic protein (GFAP) and Ibα-1 were observed post chia seed supplementation. 30110883 2018
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease
0.600 Biomarker disease BEFREE Insulin degrading enzyme contributes to the pathology in a mixed model of Type 2 diabetes and Alzheimer's disease: possible mechanisms of IDE in T2D and AD. 29222348 2018
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease
0.600 AlteredExpression disease BEFREE However, IDE mRNA was higher in cortex of AD cases (SMD = 0.71, 95% CI [0.14, 1.29], p = 0.01), not in hippocampus (SMD = -0.26, 95% CI [-0.58, 0.06]). 29357797 2018
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease
0.600 AlteredExpression disease BEFREE Neprilysin levels were not different in AD liver samples, while cathepsin D and insulin-degrading enzyme were significantly altered in AD subjects. 30192871 2018
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease
0.600 Biomarker disease BEFREE The mechanism of IDE catalyzed degrading of Aβ peptides, which is of fundamental importance in the design of therapeutic methods for Alzheimer's disease, has not been fully understood. 30133282 2018
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease
0.600 AlteredExpression disease BEFREE Although it is indispensable in removing plaques related to onset Alzheimer's disease (AD) and in degrading insulin related to diabetes, there have been few studies on the dynamic level of IDE in different stages of AD. 29680859 2018
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease
0.600 AlteredExpression disease BEFREE Consequently, specific allosteric activation of IDE coupled with state-of-the-art compound delivery and CRISP-Cas9 technique of transgene insertion can be instrumental in the fight against AD and related neurodegenerative maladies. 29132916 2018
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease
0.600 AlteredExpression disease BEFREE We showed the decreased expression level of IDE and the activating of cAMP/PKA signaling pathway in AD and T2D mice. 28771808 2018
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease
0.600 Biomarker disease BEFREE As evidence indicates potential roles for IDE in diabetes and AD, understanding the mechanisms regulating IDE expression may be important in developing new treatment strategies. 29940507 2018
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease
0.600 Biomarker disease BEFREE IDE is the common link between AD and Type II diabetes as insulin is an IDE target as well. 30338033 2018
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease
0.600 Biomarker disease BEFREE Insulin-degrading enzyme (IDE) is a zinc metalloprotease that selectively degrades biologically important substrates associated with type 2 diabetes and Alzheimer's disease (AD). 30305381 2018
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease
0.600 Biomarker disease BEFREE Our findings suggest that therapeutic and/or preventative approaches combining resveratrol and IDE may hold promise for sporadic AD. 30411033 2018
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease
0.600 Therapeutic disease RGD Treadmill Exercise Ameliorates Spatial Learning and Memory Deficits Through Improving the Clearance of Peripheral and Central Amyloid-Beta Levels. 29948724 2018
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease
0.600 Biomarker disease BEFREE Taken together, our study demonstrated that the deletion of CB2R reduces exogenous Aβ degradation and aggravates the toxicity of Aβ via the reduction of ACE and IDE, which suggests that CB2R is involved in the onset of AD and a potential therapeutic target for AD. 29991137 2018
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease
0.600 AlteredExpression disease BEFREE Protein levels of insulin-degrading enzyme (IDE), which is linked to insulin signaling and degrades Aβ, significantly increased in the 3xTg-AD mice brain compared with non-transgenic mice, and were further increased by APO. 28550243 2017
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease
0.600 Therapeutic disease RGD Multifunctional Compound AD-35 Improves Cognitive Impairment and Attenuates the Production of TNF-α and IL-1β in an Aβ25-35-induced Rat Model of Alzheimer's Disease. 28157092 2017
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease
0.600 Biomarker disease BEFREE In the present study, we measured plasma levels of amyloid-β1-42(0.142±0.029μg/L)and furin(2.292±1.54μg/L), together with those of the metalloproteinases, insulin-degrading enzyme(1.459±1.14μg/L) and neprilysin(0.073±0.015μg/L), in order to develop biomarkers for AD. 28719622 2017
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease
0.600 Therapeutic disease RGD Neuroprotective mechanism of 28553348 2017
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease
0.600 Therapeutic disease RGD Pioglitazone ameliorates Aβ42 deposition in rats with diet-induced insulin resistance associated with AKT/GSK3β activation. 28447730 2017